Page 51 - ebook
P. 51

Poster Title
                            Ovarian Cancer Stem cells targeted anti-CD44 conjugated, and cisplatin loaded PLGA nanoparticles on





                                                                                                                      tumor associated macrophages embedded 3D spheroid models
                                                                                                                                                                                                          ㅇ ㅇ ㅇ ㅇ



                                                                                                                                          Researchers’/Presenters’ Names







                                                                                                                                                               Institution/Organization/Company








                                                                                                                                                                    Shrestha Samjhana , Simmyung Yook *                                                                                                                                                              1
                                                                                                                                                                                                                                                                     1






                                                                                                                                                               1   College of pharmacy, Keimyung University, Daegu, 42601, Republic of Korea








                                                                                                    Abstract                                                                                                                                                                                                                                                          Results











              Background: The presence of cancer stem cells (CSCs) and their interplay with tumor associated                                                                                                                                                    Characterization of Cis-loaded PLGA nanoparticles




              macrophage (TAM) have made ovarian cancer (OC) drug resistant toward Cisplatin (Cis). CSC surface


                                                                                                                                                                                                                                                                     0.6
              marker CD44 targeted therapy using PLGA nanoparticles can be an attractive therapeutic strategy for                                                                                                                                                                                               y = 0.0006x - 0.0176                                                  Average size of PLGA NPs                                                                    119.8 nm ± 1.84 nm



              treatment of recurrent OC. In this study, since 3D culture spheroids models can mimic the OC tumor                                                                                                                                                     0.5                                               R² = 0.997




              microenvironment, we developed 3D cancer model in the presence of TAM and evaluated the effect of                                                                                                                                                      0.4                                                                                                              Loading capacity (LC) of Cis on PLGA                                                        5.55 % ± 0.12%



              CD44 targeted and Cis-loaded PLGA nanoparticles (anti-CD44-Cis-PLGA NPs) for treatment of recurrent                                                                                                                                                 Abosrbance   0.3                                                                                                    NPs




              OC.                                                                                                                                                                                                                                                                                                                                                                     Encapsulation efficiency (EE) of Cis on  18.5% ± 0.41%

                                                                                                                                                                                                                                                                     0.2                                                                                                              PLGA NPs

              Methods: Cis was loaded in PLGA with double emulsion solvent evaporation procedure. The formulation

                                                                                                                                                                                                                                                                     0.1
              is characterized by average particle size, zeta potential and polydispersity (PDI), loading capacity (LC)                                                                                                                                                                                                                                                               Conjugation efficiency (CE) of anti-                                                        61.73% ± 10.1 %



                                                                                                                                                                                                                                                                        0                                                                                                             CD44 on PLGA NPs
              and encapsulation efficiency (EE). The surface modification of Cis-loaded PLGA was done by EDC/NHS                                                                                                                                                           0             200            400             600            800            1000           1200


                                                                                                                                                                                                                                                                                                          Concentration (ug/ml)
              chemistry and is characterized by pierce bichinchoninic acid (BCA) protein assay.



                                                                                                                                                                                                                                                                                           Fig 4: Calibration curve of Cis                                                                    Table 1: Characteristics of Cis loaded PLGA nanoparticles
              Results: The average particle size and PDI of Cis-loaded PLGA were119.8 ±1.84 nm and 0.14 ± 0.02,



              respectively. The LC and EE were 5.55 ± 0.12 % and 18.5 ± 0.417% respectively.
                                                                                                                                                                                                                                                                              6


              Conclusion: Our results demonstrated that the Cis-PLGA NPs were successfully constructed, and this




              targeted nano system can be a potential candidate for treatment of recurrent OC.
                                                                                                                                                                                                                                                                              4




                                                                                         Introduction                                                                                                                                                                       Loading capacity %  2














              Ovarian cancer (OC) presents the heterogenous group of tumor, being the fifth major cause of

                                                                                                                                                                                                                                                                              0

              mortality among American women. OC shows high recurrence rate and chemoresistance because of                                                                                                                                                                                 10%                       20%                       30%



              the presence of cancer stem cells (CSC), with its self-renewing and differentiating ability, making OC                                                                                                                                                                             Cisplatin concentration




              more aggressive and drug resistant. The cytokines and chemokines produced by the CSC could

                                                                                                                                                                                                                                                                                         Fig 5: Loading capacity of Cis

              convert macrophages into tumor associated macrophages (TAM-M2, alternatively activated)                                                                                                                                                                                                                                                                                     Fig 6: FTIR spectra of PLGA NPs, free Cis and Cis-PLGA NPs.



              phenotype from TAM-M1 (anti-tumor) phenotype, creating a complex OC microenvironment                                                                                                                                                                 Conjugation of CD44 antibody on PLGA nanoparticles




              increasing the stemness. The 3D model of cell mimics this intricate tumor microenvironment allowing

                                                                                                                                                                                                                                                                        0.15                                                                                                                           80

              to showing appropriate tissue physiology and structure.
                                                                                                                                                                                                                                                                        0.14                                  y = 0.0378x + 0.064

              The standard management procedure for OC is surgical tumor debulking followed by radiotherapy or                                                                                                                                                          0.13                                        R² = 0.9998                                                                        60




              chemotherapy such as cisplatin. The main problem for this standard treatment is the                                                                                                                                                                       0.12



              chemoresistance by the OC due to the presence of multiple drug resistance (MDR) mechanism and                                                                                                                                                            Absorbance  0.11                                                                                                            Conjugation efficiency %  40




              the short circulation time of cisplatin. This can be solved using polymeric nanoparticles (NP) due to                                                                                                                                                       0.1

                                                                                                                                                                                                                                                                        0.09

              their sustained release of drug capability. Additionally, the possible side effects and MDR can be                                                                                                                                                        0.08                                                                                                                           20



              minimized by active targeting to CD44, which are overly expressed in the OC stem cells. Thus, we                                                                                                                                                          0.07

                                                                                                                                                                                                                                                                                                                                                                                                         0

              hypothesized that our construction of cisplatin loaded and anti-CD44 conjugated PLGA NP will                                                                                                                                                              0.06
                                                                                                                                                                                                                                                                                0                0.5                1                1.5                 2                2.5                                            1                    10                   100                   200

              provide possibility of effective treatment for the recurrent OC.                                                                                                                                                                                                                                  Concentration (ug/ul)                                                                               Antibody(Ab) concentration (ug/ml)




                                                                                                              Aims                                                                                                                                                                        Fig 7: Calibration curve of BCA                                                                                        Fig 8: Antibody conjugation efficiency











              Our aim is to evaluate the response of M2 phenotypic – TAM on the stemness of OC by the                                                                                                                                                                  Optimization of tumor spheroid




              synthesized and characterized a CD44 antibody incorporated cisplatin loaded PLGA for a targeted



              delivery of drug.





                                                                                                  Methods











              1. Synthesis of Cis-PLGA NP




              Cisplatin is loaded in PLGA NP by double emulsion solvent evaporation method. Here, we dissolved




              30 mg of cisplatin and 70 mg of PLGA NP in 20 ml of dimethyl formamide. 15 ml of 1% PVA solution




              was then added dropwise with stirrer on. The solution was probe sonicated and purified at 12000



              rpm for 12 min. The loading capacity and encapsulation efficiency was measured by UV-Vis




              spectroscopy.

























                                                                                                                                                                                                                                                                                  Fig 9: Optimization of cell density for 3D-spheroid                                                                                                  Fig 10: Spheroid diameter



                                                                              Fig 1: Schematic representation of Cis loaded PLGA


                 2. Synthesis of conjugation of anti-CD44 and PLGA NP                                                                                                                                                                                                                                                                                     Conclusion





                 2 mg of lyophilized PLGA NP was dissolved in buffer solution, where the anti-CD44 was added after



                 the stimulation of -COOH end of PLGA NP by the cross linking of EDC/NHS. The conjugation




                 efficiency was evaluated against the concentration gradient of BSA assay.                                                                                                                                                                       Thus, we have successfully constructed anti-CD44 conjugated Cis-loaded PLGA NP with good entrapment



                                                                                                                                                                                                                                                                 efficiency. We are planning to incorporate M2 phenotypic TAM into the 3D spheroid of SKOV3 cell line for the




                                                                                                                                                                                                                                                                 further cytotoxicity study of the constructed formulation (anti-CD44-Cis-PLGA NP).












                                                                           Fig 2: Schematic illustration of antibody conjugation                                                                                                                                                                                                   Acknowledgement
               3. Preparation of 3D spheroid model





               Spheroids were prepared using Aggrewell                                                             TM       400 plates, where 100ul anti-adherence rinsing



               solution was used for rinsing the plates. The plates were washed with PBS and then loaded with cell                                                                                                                                                  This research was supported by the BK21 fourth program through the National Research Foundation (NRF)




               along with 2.5% Matrigel. The plates were centrifuged at 100g for 3 min and left for incubation at                                                                                                                                                   funded by the Ministry of Education of Korea.




               37°C and 5% CO2.




























                                                                          Fig 3: Schematic presentation of 3D spheroid
   46   47   48   49   50   51   52   53   54   55   56